Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
Patients went out-of-network 3.5 times more often to see a behavioral health clinician than a medical/surgical clinician in 2021, and up to 20 times more often…
Headline
States can apply through May 20 for up to $2 million to partner with communities to integrate primary and behavioral health care in clinical practices and $900…
Perspective
Two presidents that America honors with a federal holiday on Monday shared a number of memorable traits. George Washington and Abraham Lincoln were blessed…
Headline
Two guests discuss a care network launched by Indiana University Health to spark social connection and community in light of the U.S. Surgeon General’s 2023…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 14 held a hearing on AHA-supported legislation to reauthorize through 2029 the Dr. Lorna Breen Health…
Headline
AHA Jan. 30 voiced support for bipartisan, bicameral legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care Provider Protection Act, which…